Life Sciences

Frost & Sullivan's expertise in Life Sciences research and consulting includes work in diversified strategic and operational areas

The life sciences industry is undergoing rapid change, dynamic discoveries and pressures driving business decisions and corporate growth. Business models are being forced to evolve as healthcare continues to shift from a treatment focus to points of wellness, prediction, personalization, and prevention.

Recognizing the interdependence of the payer, provider and pharmaceutical value chains, companies are re-inventing strategies in multitude ways: increased outsourcing, co-development and patient engagement are the new norms.

The Frost & Sullivan Global Life Sciences Program helps you better understand stakeholder dynamics as the healthcare system transitions from acute care into integrated care. Our research and insights help you make informed strategic decisions around how best to navigate this complex market.

We can support needs from syndicated research to projects ranging from proprietary strategic engagements and market research, marketing solutions, and whitepapers, all leveraging the global reach of our firm to propel your business forward.

We believe a structured partnership that provides you transformational insights through online content as well as deeper interaction with our senior analyst team will help ensure greater relevancy of insights provided for your organization.

  1. 05 Apr 2023  |  Asia Pacific  |  Market Outlook

    Asia-Pacific Pharmaceutical Industry Outlook, 2023

    Disruptive Technology Adoption and Outsourcing Growth is Advancing Innovation in the Pharmaceutical Industry

    Asia-Pacific’s pharmaceutical market is forecast to record 4.2% growth from 2022 to 2027, with China and Japan dominating the market in terms of value. Generics dominate the regional markets based on volume, directly impacting innovator molecule uptake. Nevertheless, Asia-Pacific is establishing itself as a global innovation hub, with China, Japa...

    $4,950.00

    Special Price $4,455.00 save 10 %

  2. 10 Jan 2020  |  Asia Pacific  |  Market Research

    Growth Insights on China’s Pharmaceutical Industry, Forecast to 2025

    Expedited Regulatory Reviews, Accompanied by Surging Novel Drug Pipelines and a Realigned Distribution System will Propel the Chinese Pharma Industry

    With over-4000 pharmaceutical players, China is the second largest pharmaceutical industry globally. Although highly fragmented, global pharma and biopharmaceutical players such as Novartis, Novo Nordisk, and AstraZeneca, have a significant hold capturing at least 8-10Percentage of the market. The market being highly dependent on its distributor ne...

    $10,000.00

    Special Price $7,500.00 save 25 %